Rossari Biotech Q2 FY27 Results: Consolidated Net Profit ₹38.91 Crore on Total Income of ₹698.16 Crore
Earnings
Chemicals - Speciality
Blacklitt Research3 min read
ТимофейЛееСуда, via Wikimedia Commons (CC0 1.0). Illustrative image.
Rossari Biotech reported consolidated total income of ₹698.16 crore and net profit of ₹38.91 crore for the quarter ended 30 Sep 2026. Standalone total income was ₹496.96 crore and net profit was ₹34.23 crore.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹698 crore, up 18.8% YoY, down 0.3% QoQ
Net profit: ₹38.91 crore, up 5.5% YoY, up 10.9% QoQ
EPS: ₹7.02, against ₹6.66 in Q2 FY26
Depreciation: ₹30.10 crore, up 65.1% YoY
Standalone
The company on its own, without its subsidiaries
Total income: ₹497 crore, up 18.1% YoY, up 2.6% QoQ
Net profit: ₹34.23 crore, up 9.5% YoY, down 0.1% QoQ
EPS: ₹6.18, against ₹5.64 in Q2 FY26
Depreciation: ₹10.73 crore, up 46.2% YoY
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
698.16
587.71
+18.8%
700.39
-0.3%
Revenue from operations
697.56
586.11
+19.0%
697.20
+0.1%
Other income
0.60
1.60
-62.5%
3.19
-81.2%
38.91
36.88
+5.5%
35.10
+10.9%
Finance costs
8.68
6.09
+42.5%
10.98
-20.9%
Depreciation
30.10
18.23
+65.1%
25.62
+17.5%
Tax expense
10.36
12.80
-19.1%
12.58
-17.6%
Net profit margin
5.57%
6.28%
-0.70 pp
5.01%
+0.56 pp
Tax as share of profit before tax
21.2%
26.0%
-4.79 pp
26.6%
-5.41 pp
EPS, basic (₹)
7.02
6.66
+5.4%
6.34
+10.7%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Sales grew faster than profit, and the gap opens below the operating line. Revenue from operations rose 19.0% to ₹697.56 crore but net profit only 5.5% to ₹38.91 crore, and profit before tax slipped 0.8% to ₹48.80 crore from ₹49.20 crore. Depreciation rose ₹11.87 crore to ₹30.10 crore (+65.1%) and finance costs ₹2.59 crore to ₹8.68 crore (+42.5%), which is why pre-tax profit did not grow with income.
A lower tax rate carried the profit. Tax took 21.2% of profit before tax against 26.0% a year earlier; at the earlier rate the charge would have been about ₹2.3 crore higher. The filing does not explain the lower rate.
Against Q1 FY27 total income was flat (down 0.3%) while net profit rose 10.9% to ₹38.91 crore from ₹35.10 crore, helped by lower finance costs (₹8.68 crore from ₹10.98 crore) and a lower tax rate (21.2% against 26.6%), partly offset by depreciation up 17.5%. For H1 FY27 total income is ₹1,398.55 crore (+23.5%) and net profit ₹74.01 crore (+5.0%).
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
496.96
420.91
+18.1%
484.46
+2.6%
Revenue from operations
495.27
419.51
+18.1%
482.27
+2.7%
Other income
1.69
1.40
+20.7%
2.19
-22.8%
34.23
31.25
+9.5%
34.27
-0.1%
Finance costs
2.08
2.49
-16.5%
3.84
-45.8%
Depreciation
10.73
7.34
+46.2%
8.34
+28.7%
Tax expense
11.92
10.72
+11.2%
12.16
-2.0%
Net profit margin
6.89%
7.42%
-0.54 pp
7.07%
-0.19 pp
Tax as share of profit before tax
25.8%
25.5%
+0.29 pp
26.2%
-0.37 pp
EPS, basic (₹)
6.18
5.64
+9.6%
6.19
-0.2%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone profit grew faster than the group's: net profit rose 9.5% to ₹34.23 crore on income up 18.1% to ₹496.96 crore, with the tax rate steady (25.8% against 25.5%) and profit before tax up 10.0% to ₹46.15 crore. Depreciation rose 46.2% to ₹10.73 crore, but finance costs fell to ₹2.08 crore from ₹2.49 crore. For H1 FY27 standalone profit is ₹68.50 crore, up 19.2%, against 5.0% for the group.
The subsidiaries add income but little profit and most of the borrowing. They add ₹201.20 crore of total income but only ₹4.68 crore of net profit, a net margin of 5.6% for the group against 6.9% standalone, and the group's finance costs of ₹8.68 crore are about four times the company's own ₹2.08 crore. All of the consolidated profit belongs to the owners, with no minority share.
The group deals in specialty chemicals and reports one segment. The consolidated results include four foreign subsidiaries, two step-down foreign subsidiaries, four Indian subsidiaries, an associate and a joint venture; Rossari (Singapore) Pte Ltd, one of the foreign subsidiaries, was incorporated on 18 Dec 2025. The same board meeting approved the leasing of land by Rossari International Limited Company, a wholly owned subsidiary, for a greenfield manufacturing facility in Saudi Arabia; the project plan, including its nature and the overall investment, will go to the board once finalised. During the quarter 2,500 equity shares were allotted to employees who exercised options. The results were reviewed by the audit committee and the statutory auditors carried out a limited review.
Inference
The group's profit is growing less than a third as fast as its sales: depreciation and finance costs are rising faster than income, and a lower tax rate is doing part of the work. The filing gives no product or volume breakdown, so it does not say what is behind the higher depreciation, or whether the Saudi Arabia facility will add to it.
For shareholders, the cost and timing of the Saudi project are not yet known, so its effect on future depreciation, interest and funding cannot be read from this announcement.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
